IGF1 and neoplasm: A pivotal cause for the enhancement of ET anti-tumor activity by fasting or FMD appears to be the reduction in blood insulin, IGF1 and leptin, with the consequent inhibition of the PI3K–AKT–mTOR pathway, at least in part through the upregulation of EGR1 and PTEN (121).